Long-term adherence and persistence with febuxostat among male patients with gout in a routine clinical setting

References

• Schlesinger N. Difficult-to-treat gouty arthritis: a disease warranting better management. Drugs 2011;71(11):1413–39.
   PubMed Web of Science ®Google Scholar
• McClory J, Said N. Gout in women. Med Health R I. 2009;92(11):363.
   PubMedGoogle Scholar
• Mikuls TR, MacLean CH, Olivieri J, Patino F, Allison JJ, Farrar JT, et al. Quality of care indicators for gout management. Arthritis Rheum. 2004;50(3):937–43.
   PubMed Web of Science ®Google Scholar
• Riedel AA, Nelson M, Joseph-Ridge N, Wallace K, MacDonald P, Becker M. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004;31:1575–81.
   PubMed Web of Science ®Google Scholar
• Dalbeth N, House ME, Horne A, Petrie KJ, McQueen FM, Taylor WJ. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout. BMC Musculoskelet Disord. 2012;13(1):174.
   PubMedGoogle Scholar
• Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis & Rheumatism. 2004;51(3):321–5.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–7.
   PubMed Web of Science ®Google Scholar
• Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705.
   PubMed Web of Science ®Google Scholar
• Scheepers L, van Onna M, Stehouwer CDA, Singh JA, Arts ICW, Boonen A. Medication adherence among patients with gout: a systematic review and meta-analysis. Semin Arthritis Rheum. 2018;47(5):689–702.
   PubMed Web of Science ®Google Scholar
• Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81(7):925–34.
   PubMed Web of Science ®Google Scholar
• Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther. 2009;11(2):R46.
   PubMed Web of Science ®Google Scholar
• Halpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Curr Med Res Opin. 2009;25(7):1711–9.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Avorn J, Levin R, Brookhart MA. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis. 2007;67(5):609–13.
   PubMed Web of Science ®Google Scholar
• Singh JA, Hodges JS, Asch SM. Opportunities for improving medication use and monitoring in gout. Ann Rheum Dis. 2009;68(8):1265–70.
   PubMed Web of Science ®Google Scholar
• Mantarro S, Capogrosso-Sansone A, Tuccori M, Blandizzi C, Montagnani S, Convertino I, et al. Allopurinol adherence among patients with gout: an Italian general practice database study. Int J Clin Pract. 2015;69(7):757–65.
   PubMed Web of Science ®Google Scholar
• De Vera MA, Marcotte G, Rai S, Galo JS, Bhole V. Medication adherence in gout: a systematic review. Arthritis Care Res (Hoboken). 2014;66(10):1551–9.
   PubMed Web of Science ®Google Scholar
• Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008;28(4):437–43.
   PubMed Web of Science ®Google Scholar
• Lee S, So MW. Adherence with urate-lowering therapies among male patients with gout in a routine clinical setting. Mod Rheumatol. 2016;26(6):950–5.
   PubMed Web of Science ®Google Scholar
• Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20(3):895–900.
   PubMed Web of Science ®Google Scholar
• Harrold LR, Andrade SE, Briesacher B, Raebel MA, Fouayzi H, Yood RA, et al. The dynamics of chronic gout treatment: medication gaps and return to therapy. Am J Med. 2010;123(1):54–9.
   PubMed Web of Science ®Google Scholar
• Zandman-Goddard G, Amital H, Shamrayevsky N, Raz R, Shalev V, Chodick G. Rates of adherence and persistence with allopurinol therapy among gout patients in Israel. Rheumatology (Oxford). 2013;52(6):1126–31.
   PubMed Web of Science ®Google Scholar
• Horsburgh S, Norris P, Becket G, Arroll B, Crampton P, Cumming J, et al. Allopurinol use in a New Zealand population: prevalence and adherence. Rheumatol Int. 2014;34(7):963–70.
   PubMed Web of Science ®Google Scholar
• Singh JA, Shah N, Edwards NL. A cross-sectional internet-based patient survey of the management strategies for gout. BMC Complement Altern Med. 2016;16(1):90.
   PubMedGoogle Scholar
• McGowan B, Bennett K, Silke C, Whelan B. Adherence and persistence to urate-lowering therapies in the Irish setting. Clin Rheumatol. 2014;35(3):715–21.
   PubMed Web of Science ®Google Scholar
• de Klerk E, van der Heijde D, Landewe R, van der Tempel H, Urquhart J, van der Linden S. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol. 2003;30:44–54.
   PubMed Web of Science ®Google Scholar
• Rashid N, Coburn BW, Wu YL, Cheetham TC, Curtis JR, Saag KG, et al. Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system. J Rheumatol. 2015;42:504–12.
   PubMed Web of Science ®Google Scholar
• Baggarly SA, Kemp RJ, Wang X, Magoun AD. Factors associated with medication adherence and persistence of treatment for hypertension in a Medicaid population. Res Social Adm Pharm. 2014;10(6):e99–112.
   PubMed Web of Science ®Google Scholar
• Rodriguez F, Cannon CP, Steg PG, Kumbhani DJ, Goto S, Smith SC, et al. Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry. Clin Cardiol. 2013;36(12):721–7.
   PubMed Web of Science ®Google Scholar
• Silva L, Miguel ED, Peiteado D, Villalba A, Mola M, Pinto J, et al. Compliance in gout patients. Acta Reumatol Port. 2010;35(5):466–74.
   PubMedGoogle Scholar
• Harrold LR, Yood RA, Mikuls TR, Andrade SE, Davis J, Fuller J, et al. Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis. 2006;65(10):1368–72.
   PubMed Web of Science ®Google Scholar